Compare ANVS & DTF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANVS | DTF |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.1M | 80.0M |
| IPO Year | 2019 | 1995 |
| Metric | ANVS | DTF |
|---|---|---|
| Price | $2.24 | $11.35 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $13.50 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 11.1K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.54 | $11.14 |
| 52 Week High | $5.50 | $11.60 |
| Indicator | ANVS | DTF |
|---|---|---|
| Relative Strength Index (RSI) | 55.41 | 41.57 |
| Support Level | $1.92 | $11.26 |
| Resistance Level | $2.38 | $11.48 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 69.40 | 21.10 |
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing mainly in a diversified portfolio of investment-grade tax-exempt obligations.